Pay in 4 interest-free payments of $5.38 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
April 1, 2025
Fas 3-studien Surmount 1 publiceras i New England Journal of Medicine
Phase 3 trials evaluating oral semaglutide in early-stage symptomatic Alzheimers disease did not meet their primary endpoints, tempering the earlier hypothesis that GLP-1s might offer direct neuroprotective benefits
Fatal outcomes documented at therapeutic doses: The first documented case of a pregnant woman dying from liver failure after taking normal, recommended doses of acetaminophen
US$ 20.66
US$ 21.34
US$ 22.17
US$ 22.75
